Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
As glargine, an analog of human insulin, is increasingly used during pregnancy, a meta-analysis assessed its safety in this population. A systematic literature search identified studies of gestational or pregestational diabetes comparing use of insulin glargine with human NPH insulin, with at least 15 women in both arms. Data was extracted for maternal outcomes (weight at delivery, weight gain, 1st/3rd trimesterHbA1c, severe hypoglycemia, gestation/new-onset hypertension, preeclampsia, and cesarean section) and neonatal outcomes (congenital malformations, gestational age at delivery, birth weight, macrosomia, LGA, 5 minute Apgar score>7, NICU admissions, respiratory distress syndrome, neonatal hypoglycemia, and hyperbilirubinemia). Relative risk ratios and weighted mean differences were determined using a random effect model. Eight studies of women using glargine (331) or NPH (371) were analyzed. No significant differences in the efficacy and safety-related outcomes were found between glargine and NPH use during pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Preventive Medicine · doi:10.1016/j.ypmed.2007.08.012 · Cited by 2,698
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 1×
“5-fold higher affinity for the IGF-1 receptor and an 8fold greater mitogenic action in comparison to insulin [31].”
BackgroundManaging preexisting diabetes for pregnancy
Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., et al. (2008) · Diabetes Care · doi:10.2337/dc08-9020 · Cited by 476
collaborators, O. B. O. T. A. D., O’Sullivan, E. P., Avalos, G., O’Reilly, M., Dennedy, M. C., Gaffney, G., & Dunne, F. (2011) · Diabetologia · doi:10.1007/s00125-011-2150-4 · Cited by 307 · cited 1×
“Fetal complications include congenital malformations, premature delivery, perinatal death, macrosomia and traumatic delivery, neonatal hypoglycemia or respiratory distress, admission to a neonatal intensive care unit, and risk of developing obesity or diabetes later in life [4, 9–25].”
BackgroundConsequences of Fetal Exposure to Maternal Diabetes in Offspring
Fetita, L.-S., Sobngwi, E., Serradas, P., Calvo, F., & Gautier, J.-F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0624 · Cited by 299 · cited 1×
“Becausemany of these problemsmay be reduced by improved glycemic control [26], efforts to maintain nearly normal levels of glucose are recommended during pregnancy associated with diabetes, frequently requiring the use of insulin.”
BackgroundLawlor, D. A., Lichtenstein, P., & Långström, N. (2011) · Circulation · doi:10.1161/circulationaha.110.980169 · Cited by 273
Low socioeconomic status is a risk factor for preeclampsia: the Generation R Study
Silva, L. M., Coolman, M., Steegers, E. A., Jaddoe, V. W., Moll, H. A., Hofman, A., Mackenbach, J. P., & Raat, H. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282fcc36e · Cited by 250 · cited 1×
“Maternal complications are also impacted by socioeconomic status and race; several studies have found that low socioeconomic status and nonwhite races are substantial risk factors for preeclampsia [53–55].”
BackgroundGestational Diabetes Mellitus: A Survey of Perinatal Complications in the 1980s
Hod, M., Merlob, P., Friedman, S., Schoenfeld, A., & Ovadia, J. (1991) · Diabetes · doi:10.2337/diab.40.2.s74 · Cited by 188
Diabetes and obesity in pregnancy
Simmons, D. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.006 · Cited by 134 · cited 1×
“Studies have found that, similar to diabetes, obesity is associated with an increased risk of the same adverse outcomes including gestational hypertension, preeclampsia, cesarean section, stillbirth, congenital malformations, and macrosomia [50, 51].”
BackgroundInsulin Glargine Safety in Pregnancy
Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G. (2010) · Diabetes Care · doi:10.2337/dc09-1045 · Cited by 104
Use of insulin glargine during pregnancy
PÖYHÖNEN‐ALHO, M., RÖNNEMAA, T., SALTEVO, J., EKBLAD, U., & KAAJA, R. J. (2007) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/00016340701515282 · Cited by 52
Tan, P. C., Ling, L. P., & Omar, S. Z. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2008.11.038 · Cited by 51 · cited 1×
“Hindawi Publishing Corporation Obstetrics and Gynecology International Volume 2012, Article ID 649070, 11 pages doi:10.1155/2012/649070”
BackgroundInfluentialUse of glargine in pregnant women with type 1 diabetes mellitus: a case-control study
IMBERGAMO, M., AMATO, M., SCIORTINO, G., GAMBINA, M., ACCIDENTI, M., CRISCIMANNA, A., GIORDANO, C., & GALLUZZO, A. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.013 · Cited by 46
Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802638170 · Cited by 45
Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy
Smith, J., Manuck, T., White, J., & Merrill, D. (2009) · American Journal of Perinatology · doi:10.1055/s-0028-1095181 · Cited by 22 · cited 4×
“The incidence of macrosomia [35, 39, 41, 42], LGA infants [35, 37–39], and 5-minute Apgar scores <7 [37– 39, 42] were each reported in four of the eight studies.”
BackgroundResultInfluential
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002960 · Cited by 470
Metadata
- Authors
- Lepercq, J., Lin, J., Hall, G. C., Wang, E., Dain, M.-P., Riddle, M. C., & Home, P. D.
- Venue
- Obstetrics and Gynecology International
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-11
- ISSN
- 1687-9589 (ISSN-L)
- 1687-9597
- OpenAlex
- W1969558304
- Cited by
- 95
- References
- 17
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.